CollPlant Biotechnologies (NASDAQ: CLGN) announced that AbbVie, through its subsidiary Allergan Industrie SAS, exercised its right to terminate the company’s February 2021 development agreement on April 9 2026, with the partnership officially ending on June 8 2026. The announcement on April 13 2026 confirmed the termination and the loss of a key revenue stream that had previously provided up to $26 million in milestone payments, of which $10 million had already been received in June 2023 and $14 million was paid upfront in 2021.
In response to the loss of AbbVie’s partnership, CollPlant disclosed a 50% reduction in headcount on April 13 2026. The company said the cost‑cutting measures are expected to extend its cash runway into the fourth quarter of 2026, giving it time to secure new financing or partner agreements to sustain operations and continue product development.
CollPlant’s financial results for the fourth quarter of 2025 showed revenue of $2.29 million, exceeding analyst estimates by 47%, but the company posted a wider net loss. Earlier, on March 26 2026, the company reported GAAP revenue of $2.4 million for the year, a sharp increase from $515,000 in 2024, largely driven by a $2 million payment from AbbVie. These figures illustrate the company’s reliance on the AbbVie partnership and the financial impact of its termination.
The company’s CEO, Yehiel Tal, stated that the cost‑reduction plan will extend the cash runway into Q4 2026 and that the termination, while a setback, presents an opportunity to pursue new agreements across the aesthetics market, including dermal and soft‑tissue filler products. Tal emphasized that interest in CollPlant’s plant‑derived recombinant human collagen (rhCollagen) technology remains strong and that the company is actively seeking new partners for its core programs—regenerative dermal and soft‑tissue fillers, regenerative breast implants, and rhCollagen bioinks for 3D bioprinting.
CollPlant also received a notice from Nasdaq indicating non‑compliance with the minimum bid‑price requirement, with a deadline of September 21 2026 to regain compliance. The notice adds a significant risk to the company’s continued listing status and underscores the urgency of securing new revenue streams and capital to navigate the upcoming compliance window.
The termination of the AbbVie agreement, the workforce reduction, and the Nasdaq compliance issue collectively signal a period of strategic realignment for CollPlant. The company must accelerate its search for new partners, maintain disciplined cost management, and address regulatory compliance to preserve its market position and financial viability.
revised_sentiment_rating:-2}]} (Note: Sentiment rating is on a scale from -10 to 10, with negative values indicating a net negative outlook.)
revised_sentiment_rating:-2}
importance
high
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.